secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioNexus Gene Lab Corp (BGLC)
CIK:        0001737523
Form:       8-K
Filed at:   2026-07-28T18:30:39+00:00
Accession:  0001477932-26-004556
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioNexus advances VitaGuard MRD rollout in SE Asia after China visit; targets 2026 deployment
--------------------------------------------------------------------------------

- Working visit to Tongshu Gene facilities in Shanghai and Changzhou; reviewed implementation for SE Asia under license.
- VitaGuard is a tumor-naive fixed-panel liquid biopsy for MRD; currently in paid commercial use in China.
- BioNexus holds exclusive license for 10 SE Asian markets (pop. 680M); also owns ~15% of Fidelion holding international rights.
- Target cost per test under $300; initial deployment targeted in select SE Asian medical hubs during 2026.
- Fidelion in discussions with partners for markets outside SE Asia; no definitive agreement yet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737523/000147793226004556/0001477932-26-004556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737523/000147793226004556/bglc_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-26-004556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer